Neuroblastoma Recurrent clinical trials

Explore recruiting neuroblastoma recurrent clinical trials.

Recruiting neuroblastoma recurrent studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuroblastoma Recurrent trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Denmark, France, Germany, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Neuroblastoma Recurrent trials by city

Neuroblastoma Recurrent clinical trials

Recruiting neuroblastoma recurrent studies right now

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Also recruiting in Europe

A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Neuroblastoma Recurrent trials by city

Other conditions